The FDA has approved Anthim (obiltoxaximab; Elusys) injection for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial agents, and for the ...

The BARDA-supported monoclonal antibody was approved both as a treatment after anthrax exposure and as an anthrax prophylactic. FDA announced on March 21, 2016, it has approved Anthim (obiltoxaximab), ...

For 2022, NightHawk generated revenues of $6.4 million and posted a net loss of ($43.4) million, or ($1.70) per share. As of December 31, 2022, NightHawk holds a cash balance of $44.3 million. For the ...

On Friday, March 18, the U.S. Food and Drug Administration approved the Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is ...

Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023 Reaffirms ANTHIM as an important medical countermeasure in the U.S.

First funding awarded by BARDA (Biomedical Advanced Research & Development Authority) for development of an intramuscular formulation of an anthrax anti-toxin for pre- and post-exposure prophylactic ...

WASHINGTON, D.C. (WPVI) -- Federal health officials have approved a new injectable drug to treat patients who have been exposed to the deadly toxin anthrax. The Food and Drug Administration said it ...

The first contract year provides $16.8 million of funding with options for additional funding over the following four years. If licensed by the U.S. Food and Drug Administration (FDA), the federal ...

PINE BROOK, N.J., September 25, 2007 -- Elusys Therapeutics, Inc. (Elusys), a privately held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening ...

On Friday, March 18, the U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also ...

PINE BROOK, N.J., Dec. 7 Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, ...